Libros sobre el tema "Metalloproteinases Inhibitors Therapeutic use"

Rotheim, Philip. New developments in therapeutic enzyme inhibitors and receptor blockers. Norwalk, CT: Business Communications Co., 1996.

Goudot-Perrot, Andrée. Metabolic inhibitors: Antibiotics - antimitotics - psychotropics. Stuttgart: Schwer Verlag, 1992.

Co, Business Communications. New developments in therapeutic enzyme inhibitors and blockers. Norealk, CT: Business Communications Co., 2002.

George, Weinbaum, Giles Ralph E, Krell Robert D, New York Academy of Sciences. y American Thoracic Society, eds. Pulmonary emphysema: The rationale for therapeutic intervention. New York, N.Y: New York Academy of Sciences, 1991.

PhD, Henderson Brian y Bodmer Mark W, eds. Therapeutic modulation of cytokines. Boca Raton, Fla: CRC Press, 1996.

K, Ghosh Arun. Aspartic acid proteases as therapeutic targets. Weinheim: Wiley-VCH, 2010.

K, Ghosh Arun. Aspartic acid proteases as therapeutic targets. Weinheim: Wiley-VCH, 2010.

Philippe, Taupin, ed. The cystatin superfamily of proteinase inhibitors. New York: Nova Science Publishers, 2007.

Osiadacz, Jarosław. Inhibitory topoizomeraz DNA i ich zastosowanie w chemioterapii. Wrocław: Oficyna Wydawnicza Politechniki Wrocławskiej, 1999.

Li, William W. The antiangiogenic therapy self help book for cancer patients. Cambridge, Mass: Angiogenesis Foundation, 2003.

International FOIPAN Symposium. (1988 Shizuoka, Japan). Therapeutic basis of synthetic protease inhibitor: Proceedings of the International FOIPAN Symposium held as a Satellite of the 7th International Symposium on Gastrointestinal Hormones, November 4, 1988, Shizuoka, Japan. Editado por Kanno Tomio 1933-, Miyoshi A, Biomedical Research Foundation (Japan) y International Symposium on Gastrointestinal Hormones. (7th : 1988 : Shizuoka, Japan). Tokyo: Biomedical Research Foundation, 1989.

Mantovani, Alberto. Pharmacology of cytokines. Oxford: Oxford University Press, 2000.

N, DeBrue Anne, ed. Angiotensin converting enzyme inhibitors. New York: Nova Biomedical Books, 2009.

Lane, I. William. Comprehensive research papers on the therapeutic use of shark cartilage. Kerrville, TX: Information Services, 1992.

Chiba, Tsutomu, P. Malfertheiner y Hiroshi Satoh. Proton pump inhibitors: A balanced view. Basel: Karger, 2013.

Strube, Gillian. ACE inhibitors in hypertension: A guide for general practitioners. Dordrecht: Kluwer Academic Publishers, 1992.

Shiau, Judy Y. The efficacy of proton pump inhibitors in adults with functional dyspepsia. Ottawa: Canadian Coordinating Office for Health Technology Assessment, 2002.

H, Opie Lionel. Angiotensin-converting enzyme inhibitors: Scientific basis for clinical use. New York: Wiley-Liss, 1992.

Ezio, Giacobini y Becker Robert E, eds. Current research in Alzheimer therapy: Cholinesterase inhibitors. New York: Taylor & Francis, 1988.

Chang, Henry E. HIV protease inhibitor report. 2^a ed. Brooklyn, NY (72 Orange St., #3C, Brooklyn 11201): National AIDS Treatment Advocacy Project, 1996.

National Institute for Clinical Excellence (Great Britain). Guidance on the use of donepezil, rivastigmine and galantamine for the treatment of Alzheimer's disease. London: National Institute for Clinical Excellence, 2001.

Donnelly, Raymond P. Cytokine therapies: Novel approaches for clinical indications. Boston, Mass: Blackwell Pub. on behalf of the New York Academy of Sciences, 2009.

Krul, Kenneth G. Transcription inhibitors: The next generation of therapeutics. Waltham, Mass: Decision Resources, Inc., 1996.

H, Opie Lionel. Angiotensin-converting enzyme inhibitors: Scientific basis for clinical use. New York: Wiley-Liss, 1992.

K, Ferguson Roger y Vlasses Peter, eds. Angiotensin-converting enzyme inhibitors. Mount Kisco, N.Y: Futura Pub. Co., 1987.

1943-, Greenwald Robert A., Golub Lorne M y New York Academy of Sciences., eds. Inhibition of matrix metalloproteinases: Therapeutic potential. New York, N.Y: New York Academy of Sciences, 1994.

Clendeninn, Neil J. y Krzysztof Appelt. Matrix Metalloproteinase Inhibitors in Cancer Therapy. Humana Press, 2000.

(Editor), Robert A. Greenwald, New York Academy of Sciences (Corporate Author) y Lorne M. Golub (Editor), eds. Inhibition of Matrix Metalloproteinases: Therapeutic Potential (Annals of the New York Academy of Sciences). New York Academy of Sciences, 1994.

(Editor), Robert A. Greenwald, Stanley Zucker (Editor) y Lorne M. Golub (Editor), eds. Inhibition of Matrix Metalloproteinases: Therapeutic Applications (Annals of the New York Academy of Sciences). New York Academy of Sciences, 1999.

Kevin M.K. Bottomley (Editor), David Bradshaw (Editor) y John S. Nixon (Editor), eds. Metalloproteinases as Targets for Anti-Inflammatory Drugs (Progress in Inflammation Research). Birkhäuser Basel, 1999.

(Editor), Robert A. Greenwald, New York Academy of Sciences (Corporate Author) y Lorne M. Golub (Editor), eds. Inhibition of Matrix Metalloproteinases: Therapeutic Potential (Annals of the New York Academy of Sciences, Vol 732). New York Academy of Sciences, 1994.

(Editor), Neil J. Clendeninn y Krzysztof Appelt (Editor), eds. Matrix Metalloproteinase Inhibitors in Cancer Therapy (Cancer Drug Discovery and Development). Humana Press, 2001.

Therapeutic Kinase Inhibitors. Springer, 2012.

Page, Clive, Christian Schudt, Gordon Dent y Klaus F. Rabe. Phosphodiesterase Inhibitors. Elsevier Science & Technology Books, 1996.

1957-, D'Orléans-Juste P. y Plante G. E, eds. ACE inhibitors. Basel: Birkhäuser Verlag, 2001.

Inhibitors of Cyclin-dependent Kinases as Anti-tumor Agents (Crc Enzyme Inhibitors). CRC, 2006.

Xu, Jun-Ping. Cancer Inhibitors from Chinese Natural Medicines. Taylor & Francis Group, 2016.

Xu, Jun-Ping. Cancer Inhibitors from Chinese Natural Medicines. Taylor & Francis Group, 2016.

Xu, Jun-Ping. Cancer Inhibitors from Chinese Natural Medicines. Taylor & Francis Group, 2016.

Xu, Jun-Ping. Cancer Inhibitors from Chinese Natural Medicines. Taylor & Francis Group, 2016.

Xu, Jun-Ping. Cancer Inhibitors from Chinese Natural Medicines. Taylor & Francis Group, 2021.

Xu, Jun-Ping. Cancer Inhibitors from Chinese Natural Medicines. Taylor & Francis Group, 2016.

Weinbaum, George, Ralph E. Giles y Robert D. Krell. Pulmonary emphysema : The rationale for therapeutic intervention. New York Academy of Sciences, 1991.

Machajewski, Timothy D., Zhenhai Gao, Brian Blagg, Tim Haystead y Len Neckers. Inhibitors of Molecular Chaperones As Therapeutic Agents. Royal Society of Chemistry, The, 2013.

Picard, Didier, Timothy D. Machajewski, Zhenhai Gao, David P. Rotella y Chrisostomos Prodromou. Inhibitors of Molecular Chaperones As Therapeutic Agents. Royal Society of Chemistry, The, 2013.

Aromatase inhibitors. Basel: Birkhäuser, 2006.

Brodie, Angela, J. Michael Dixon, Robert Paridaens, Miller William R y B. J. A. Furr. Aromatase Inhibitors. Springer London, Limited, 2006.

Brodie, Angela, Aman Buzdar, Per Eystein Lonning, J. Michael Dixon y B. J. A. Furr. Aromatase Inhibitors. Birkhauser Verlag, 2008.

Mousa, Shaker A. Angiogenesis Inhibitors and Stimulators: Potential Therapeutic Implications. Taylor & Francis Group, 2000.

Zhang, Jie. PARP as a Therapeutic Target (Handbooks in Pharmacology and Toxicology). CRC, 2002.